Clinical Trials Logo

Stage III Anal Cancer AJCC v8 clinical trials

View clinical trials related to Stage III Anal Cancer AJCC v8.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03233711 Active, not recruiting - Clinical trials for Anal Canal Cloacogenic Carcinoma

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Start date: July 5, 2018
Phase: Phase 3
Study type: Interventional

This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.